StrokeDx is a human health startup developing next-generation technology that will transform how strokes are diagnosed and treated. Based on technology developed at Caltech, the innovative, portable StrokeDx neuroimaging device will dramatically reduce the time to diagnose and treat strokes. Their solution leverages machine learning and AI to fuel diagnostic accuracy and imaging capabilities. The global stroke diagnostics market is expected to be ~$5.5B by 2028. Most recently, StrokeDx has been named to the MedTech Innovator (MTI) 2023 Cohort. MTI is the world’s largest and most competitive medical device accelerator. Learn more about the company at

The discussion kicked off with a presentation and introductory remarks from StrokeDx Co-founders Shane Shahrestani and Alexander Ballatori, followed by Q&A with Freeflow, and concluded with questions from the audience.

List of speakers:

Shane Shahrestani, Co-Founder at StrokeDx

Alexander Ballatori, Co-Founder at StrokeDx

David Fleck, Founder and Managing Partner, Freeflow Ventures

Kevin Barrett, Managing Partner, Freeflow Ventures